GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » Cyclically Adjusted FCF per Share

United Therapeutics (United Therapeutics) Cyclically Adjusted FCF per Share : $11.18 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

United Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was $1.440. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $11.18 for the trailing ten years ended in Dec. 2023.

During the past 12 months, United Therapeutics's average Cyclically Adjusted FCF Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 13.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 11.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 20.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of United Therapeutics was 76.90% per year. The lowest was 8.30% per year. And the median was 23.85% per year.

As of today (2024-04-27), United Therapeutics's current stock price is $233.85. United Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $11.18. United Therapeutics's Cyclically Adjusted Price-to-FCF of today is 20.92.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of United Therapeutics was 78.63. The lowest was 12.65. And the median was 23.52.


United Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for United Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Cyclically Adjusted FCF per Share Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.43 7.71 8.84 10.28 11.18

United Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.28 10.90 10.95 11.29 11.18

Competitive Comparison of United Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, United Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



United Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.44/129.4194*129.4194
=1.440

Current CPI (Dec. 2023) = 129.4194.

United Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 1.622 99.695 2.106
201406 -1.264 100.560 -1.627
201409 4.121 100.428 5.311
201412 1.646 99.070 2.150
201503 2.251 99.621 2.924
201506 0.717 100.684 0.922
201509 3.918 100.392 5.051
201512 -0.121 99.792 -0.157
201603 2.398 100.470 3.089
201606 2.458 101.688 3.128
201609 4.753 101.861 6.039
201612 3.397 101.863 4.316
201703 4.688 102.862 5.898
201706 1.109 103.349 1.389
201709 5.363 104.136 6.665
201712 -2.582 104.011 -3.213
201803 5.424 105.290 6.667
201806 2.910 106.317 3.542
201809 4.455 106.507 5.413
201812 0.764 105.998 0.933
201903 -14.931 107.251 -18.017
201906 2.559 108.070 3.065
201909 3.905 108.329 4.665
201912 1.776 108.420 2.120
202003 4.571 108.902 5.432
202006 3.284 108.767 3.908
202009 5.271 109.815 6.212
202012 2.520 109.897 2.968
202103 1.707 111.754 1.977
202106 2.789 114.631 3.149
202109 3.410 115.734 3.813
202112 2.171 117.630 2.389
202203 5.769 121.301 6.155
202206 2.287 125.017 2.368
202209 3.897 125.227 4.027
202212 1.796 125.222 1.856
202303 6.724 127.348 6.833
202306 1.244 128.729 1.251
202309 5.644 129.860 5.625
202312 1.440 129.419 1.440

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


United Therapeutics  (NAS:UTHR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=233.85/11.18
=20.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of United Therapeutics was 78.63. The lowest was 12.65. And the median was 23.52.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


United Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (United Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Paul A Mahon officer: EVP & General Counsel
Nilda Mesa director C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey director
Martine A Rothblatt director, officer: Chief Executive Officer
Louis W Sullivan director
Judy D. Olian director 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz officer: President and COO C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky director
Raymond Dwek director
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein director STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner director C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs director, officer: President and COO
David Zaccardelli officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069